Top Articles

It was this concern that prompted Regulation D, a special exemption that became effective April 15, 1982. It's not just another exemption, but rather one of the key exemptions for small business that want to raise money by se

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

lling stock to the general public. It is also considered a form of taking a company public without the burden and expenses of a full registration process with the SEC such as in a traditional Initial Public Offering.

Regulat

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

ion D consists of six basic rules. The first three are simply basic rules; they are concerned with definitions, conditions, and notification. Rule 501 covers the definitions of the various terms used in the rules. Rule 502 se

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

ts forth the conditions, limitations, and information requirements for the exemptions in rules 504, 505, and 506. Rule 503 contains the SEC notification requirements. The last three rules deal with the specifics of raising mo

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

ey. Rule 504 generally pertains to securities sales up to $1 million. Rule 505 applies to offering from $1 million to $5 million. Rule 506 is for securities offerings exceeding $5 million.

Regulation D contains the type of e

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

xemptions that many small businesspersons have been looking for. These exemptions can easily be used in private placements or "limited public offerings". Thus, a Regulation D private placement document, better known as the Pr

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

ivate Placement Memorandum, has been regarded as one of the most workable exemptions for small offerings.

While Regulation D offerings can provide a capital formation solution for a small business (the good news), it does ha

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

e some legal limitations (the not so good news). There are strict limitations placed how the solicitation process is done on these stock sales (securities) to the public as well as suitability standards that are imposed on th

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

e type of investors. These limitations drastically reduce the number of private placements that are successful. A Regulation "A" offering (another exemption) has a higher probability of success based on a more dynamic SEC exe

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

mption rule. This Exemption will be discussed in future articles.

SCOR

The Small Corporate Offering Registration, better known as SCOR, (falls under Regulation D) is designed to assist small companies in their capitalizatio

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

by issuing stock directly to the public. This process is called a Direct Public Offering or DPO since an Investment Banker does usually not underwrite the offering. A SCOR offering is an ideal format for executing a limited

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

Internet DPO. Think of a SCOR offering as a quasi-public private offering.

A SCOR candidate may raise as much as $1 million within a 12-month period with a minimum stock price of $5. Typically, the prospective SCOR candidate

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

will set a minimum amount of capital to be raised to ensure that sufficient funds will be available for growth and development before any of the funds are accessible for company use. While a SCOR offering does not contain

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

the substantial costs usually associated with larger public offerings, it is a prime candidate for an Internet DPO (On-line Direct Public Offering), which typically costs much less and provides a small company with an effecti

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

e means by which to raise capital. The filing, which consists of a form called Form U-7, is exempted from the provisions of the SEC Act of 1933 under Regulation D, which means that the DPO candidate will not have to file a fu

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

ll registration statement with the SEC. However, as with any public company, compliance with antifraud and personal liability provisions of the SEC Act of 1933 is a requirement. SEC Filing (U-7)

DPO candidates are required

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

to complete and file a FORM U-7 that has been designed with idea in mind that non- securities attorney can complete it; nevertheless, it will most likely require expert assistance. Furthermore, in some cases, 2 years of audi

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

ed financial statements are required and should be included with the Form U-7 filing.

Blue Sky; State Filing (SCOR)

Regulations at both federal and state levels must be complied within a SCOR-based DPO as well as with any I

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

PO. The State regulations are called Blue Sky laws. Blue Sky laws were designed to protect investors from "unscrupulous" issuers of stock. Since its inception in 1987, SCOR filings have been adopted in 42 states. Some states

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

may require minimum amounts to be raised before the DPO candidate may access the raised capital. Stay tuned for more information on this topic and further general articles on capital raising alternatives for small business

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.toparticles.org.ua/article/131238/toparticles-US-Regulation-D-Securities-Offerings-for-Small-Business.html">U.S. Regulation D Securities Offerings for Small Business</a>

BB link (for phorums):
[url=http://www.toparticles.org.ua/article/131238/toparticles-US-Regulation-D-Securities-Offerings-for-Small-Business.html]U.S. Regulation D Securities Offerings for Small Business[/url]

Advertising business gifts offer a tried and true method of publicizing your business. Little tokens of appreciation given to clients, promotional items offered as an incentive to try a new product and trinkets that advertise your name are all part of the broader spectrum of advertising business gifts.

Congruency is not only critical to create and build a powerful positioning and brand, but without it your company is built on a wobbly foundation that can give way any second. Without it you are sabotaging your own business! Here's why...

Tags

Links

Top Articles - U.S. Regulation D Securities Offerings for Small Business

Related Articles: